November 29, 2017
Brand Name: Juluca
Other Name(s): DTG/RPV, dolutegravir sodium/rilpivirine hydrochloride
Drug Class: Combination Drugs
Juluca can cause serious, life-threatening side effects. These include severe skin rash and allergic reactions, liver problems, and depression.
Contact your health care provider right away if you develop a rash while taking Juluca. Stop taking Juluca and get medical help right away if you develop a rash with any of the following signs or symptoms:
Some people taking Juluca have had liver problems. People with a history of hepatitis B virus infection (HBV) or hepatitis C virus infection (HCV) or who have elevated results on liver function tests may have an increased risk of developing new or worsening liver problems while taking Juluca. Liver problems have also occurred in people taking Juluca who have no history of liver disease. Liver function tests may be done before and during treatment with Juluca. Call your healthcare provider right away if you develop any of the following signs or symptoms of liver problems:
Contact your health care provider right away or get medical help if you have any of the following symptoms that could be signs of depression or mood changes:
While taking Juluca, it is important to keep all of your appointments with your health care provider.
Juluca is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to treat HIV infection in adults and to replace the current HIV regimen in people who:
Juluca is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines.
Juluca contains the following two different medicines combined in one pill:
Integrase inhibitors block an HIV enzyme called integrase and NNRTIs block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking integrase and reverse transcriptase, these two drugs work in combination to prevent HIV from multiplying and can reduce the amount of HIV in the body.
HIV medicines can't cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission.
Before taking Juluca, tell your health care provider:
Juluca comes in tablet form. Each tablet contains:
Take Juluca according to your health care provider's instructions.
Take Juluca with food (a protein drink is not a substitute for food). If you are taking any other medicines, carefully follow instructions on how to take them with Juluca.
If you take too much Juluca, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.
For more information on how to take Juluca, see the FDA drug label from DailyMed. (DailyMed is a federal website that includes the most recent drug labels submitted to FDA.)
If you miss a dose of Juluca, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
Juluca may cause side effects. Many side effects from HIV medicines, such as nausea or occasional dizziness, are manageable. See the AIDSinfo fact sheet on HIV Medicines and Side Effects for more information.
Some side effects of Juluca can be serious. Serious side effects of Juluca include severe skin rash and allergic reactions, liver problems, and depression or mood changes. (See the WARNING box above.)
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Juluca. To learn more about possible side effects of Juluca, read the drug label or package insert or talk to your health care provider or pharmacist.
You can report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online at www.accessdata.fda.gov/scripts/medwatch/.
More information about Juluca is available:
[Note from TheBody.com: This article was originally published by AIDSinfo on Nov. 27, 2017. We have cross-posted it with their permission.]
|FDA Approves First Two-Drug Regimen for Certain Patients With HIV|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.